PK and Safety of SI-722 in IC/BPS

Summary

This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.

Timeline

Start

2020-03-30

Primary completion

2021-01-12

Completion

2021-01-12

Outcome

Met primary endpoint

release “In tolerability evaluation, a primary objective of the study, the tolerability of SI-722 was confirmed, and the Company is currently considering the next-phase study.” seikagaku.co.jp ↗

Drugs

Indications